CLDI

#4986
Calidi Biotherapeutics, Inc. Common Stock
1.3 4 USD
+0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.34
1.35
Intervallo Annuale
0.09
1.91
Variazione giornaliera
+2.29%
Variazione Mensile
-17.79%
Variazione di 6 mesi
+65.47%
Variazione Annuale
+77.30%
Chiusura Precedente
1.3 1
Open
1.3 5
Minimo
1.3 4
Massimo
1.3 5
Volume
3
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Calidi Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Calidi Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Calidi Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Calidi Biotherapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Calidi Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Calidi Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Calidi Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Calidi Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Calidi Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Calidi Biotherapeutics, Inc. quarterly report, Q1 FY2026
10-Q

Calidi Biotherapeutics, Inc. current report, Q3 FY2024

Full document

Business Context and Reporting Period

Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 11, 2024
Reporting Period: Event-based disclosure for September 11, 2024.
Context: The filing discloses a scientific presentation titled "Systemic and Localized Antitumor Virotherapies" delivered by the Company and its subsidiary, Redtail Biopharma, Inc., during a webinar hosted by RedChip Companies, Inc.

Key Financial Metrics

This Form 8-K is a disclosure of a non-financial event (Regulation FD) and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

No material changes to financial position or operations are reported in this document. The filing solely references the dissemination of scientific information regarding the Company's virotherapy programs.

Guidance, Outlook, and Risks

  • Management Commentary: The Company furnished a presentation regarding its systemic and localized antitumor virotherapies. A webcast of the webinar is available on the Company's investor relations website.
  • Legal Disclaimers: The Company explicitly states that by filing this report, it makes no admission as to the materiality of the information under Regulation FD. The information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it subject to liabilities under that Section.
  • Incorporation by Reference: The information in this Item 7.01 disclosure shall not be incorporated by reference into other filings under the Securities Act or Exchange Act unless expressly set forth by specific reference.

Investor Verification Checklist

  • Verify the content of the "Systemic and Localized Antitumor Virotherapies" presentation (Exhibit 99.1) via the Company's investor website.
  • Confirm the availability of the webinar webcast on the Company's Events and Presentation page.
  • Note that this filing does not update financial guidance or operational milestones beyond the presentation itself.

Notizie